But health access groups say the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.
In one case, a fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses.
Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.
There is a possibility of Indian companies becoming part of the consortium, in the past Gilead used voluntary licenses to rope in Indian cos to manufacture and launch HIV and hepatitis-C medications in low-middle-income countries (LMICs).
"We're working with the company to emphasize the necessity of speed while at the same time to understand the data," FDA Commissioner Stephen Hahn said.
Data from the Commerce Department said gross domestic product fell at a 4.8 percent annualized rate in the January-to-March period, while economists in a Reuters poll were expecting a contraction of 4 percent.
Remdesivir has been touted by many - including President Donald Trump - as one of the more promising potential treatments for the virus.
Moneycontrol's Shraddha Sharma talks to Prince Thomas to find out what drug companies are doing to find a cure for coronavirus.
Gilead warned that those (generic versions) medicines have not been approved for use in the countries into which they are imported.
The second annual 'Change the World' list is topped by UK's GlaxoSmithkline, followed by Israel-based IDE Technologies and American conglomerate General Electric at the second and third positions, respectively.
â€œThe company has received approval for the generic version of ledipasvir + sofosbuvir combination from Drugs Controller General (India)â€, Natco Pharma said in a BSE filing today.
According to a press release issued by the Telangana government, Senior Director, South East Asia and Pacific, Aaron Brinkworth and Director, Government Affairs - Asia, Claudio Lilienfeld of Gilead Sciences met Chief Minister K Chandrasekhar Rao in camp office along with their team.
The injectable drugs, known as PCSK9 inhibitors, could cost an estimated USD 7,000 to USD 12,000 per year for each person using the drug.
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India. Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.
The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.
Shares of Dr Reddy's Laboratories gained 1.7 percent intraday Tuesday on agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Zydus Cadila had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture Sofosbuvir and the fixed dose combination of Ledipasvir/ Sofosbuvir for distribution in 91 developing countries including India.
Investors continued to buy shares of Natco Pharma on Thursday after the Hyderabad-based company received approval for Hepatitis C drug in India. The stock rallied 5.5 percent intraday to hit a record high of Rs 1,889.90. It has been rising for the five consecutive sessions today. In five days, it spiked more than 26 percent.
The Supreme Court has declined to review the Federal Circuit's decision. The case remains pending in the District of New Jersey where the validity of US Patent No 5,763,483 continues to be challenged, it added.
The US Supreme Court has declined a review of a federal circuit court ruling that favoured Natco Pharma in a patent infringement litigation over swine flu treatment drug Tamiflu.
Shares of Natco Pharma gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.
Shares of Natco Pharma gained 8.5 percent intraday on Tuesday on tie up with American biotechnology company for selling hepatitis C medicines.
Biocon had previously said it planned to list Syngene but had not given a timeline. Late on Thursday, it said its board had approved starting the process of listing and hiring merchant bankers to sell 10-15 percent from Biocon's majority stake in the unit in the public offer.
Gilead challenged Patent Controller‘s order that said Sovaldi (or Sofosbuvir) was not inventive enough under section 3 (d) of the Indian Patent Act.